Minimal intensity diode laser (810 nanometer) photocoagulation (MIP) for diffuse diabetic macular edema (DDME)

Area of Science:

• Ophthalmology
• Diabetic Retinopathy Treatment
• Laser Photocoagulation

Background:

• Diabetic macular edema (DDME) is a leading cause of vision loss in diabetic patients.
• Current treatments for DDME have limitations, including potential visual field defects and scarring.

Observation:

• This study evaluated minimal intensity diode laser (810nm) photocoagulation (MIP) for DDME.
• Patients received MIP or modified grid photocoagulation, with follow-up every 3-4 months.
• Visual acuity, visual fields, macular edema reduction, and treatment number were assessed.

Findings:

• MIP achieved reduction/elimination of DDME in approximately 74% of eyes within 24 months.
• Eighty-eight percent of patients maintained stable visual acuity.
• Factors like cystoid edema, poor initial acuity, macular ischemia, or hypertension did not negatively impact outcomes.
• Patients without systemic vascular disease showed better visual stabilization or improvement.
• MIP resulted in significantly reduced atrophic scarring and fewer pericentral visual field complaints compared to shorter wavelength lasers.

Implications:

• Minimal intensity diode laser (810nm) photocoagulation is an effective treatment for DDME.
• This technique offers advantages in preserving visual field function and minimizing retinal scarring.
• While resolution may be slightly prolonged, MIP presents a safer alternative for managing DDME.